LT3864053T - Rms gydymas, pakeičiant terapiją - Google Patents

Rms gydymas, pakeičiant terapiją

Info

Publication number
LT3864053T
LT3864053T LTEPPCT/EP2020/075332T LTEP2020075332T LT3864053T LT 3864053 T LT3864053 T LT 3864053T LT EP2020075332 T LTEP2020075332 T LT EP2020075332T LT 3864053 T LT3864053 T LT 3864053T
Authority
LT
Lithuania
Prior art keywords
rms
treatment
changing therapy
therapy
changing
Prior art date
Application number
LTEPPCT/EP2020/075332T
Other languages
English (en)
Lithuanian (lt)
Inventor
Krishnan Ramanathan
Dieter Adrian Haering
Morten Bagger
Martin MERSCHHEMKE
Marina ZIEHN
Ratnakar PINGILI
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=72709332&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3864053(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of LT3864053T publication Critical patent/LT3864053T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LTEPPCT/EP2020/075332T 2019-09-11 2020-09-10 Rms gydymas, pakeičiant terapiją LT3864053T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19196789 2019-09-11
EP20154736 2020-01-30
PCT/EP2020/075332 WO2021048280A1 (en) 2019-09-11 2020-09-10 Treatment of rms by switching therapy

Publications (1)

Publication Number Publication Date
LT3864053T true LT3864053T (lt) 2023-09-11

Family

ID=72709332

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/EP2020/075332T LT3864053T (lt) 2019-09-11 2020-09-10 Rms gydymas, pakeičiant terapiją

Country Status (15)

Country Link
US (1) US20220298253A1 (cg-RX-API-DMAC7.html)
EP (2) EP3864053B1 (cg-RX-API-DMAC7.html)
JP (2) JP7794735B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220062025A (cg-RX-API-DMAC7.html)
CN (3) CN118436777A (cg-RX-API-DMAC7.html)
AU (1) AU2020344154A1 (cg-RX-API-DMAC7.html)
CA (1) CA3150947A1 (cg-RX-API-DMAC7.html)
DK (1) DK3864053T3 (cg-RX-API-DMAC7.html)
ES (1) ES2957112T3 (cg-RX-API-DMAC7.html)
FI (1) FI3864053T3 (cg-RX-API-DMAC7.html)
IL (1) IL290619A (cg-RX-API-DMAC7.html)
LT (1) LT3864053T (cg-RX-API-DMAC7.html)
MX (1) MX2022003010A (cg-RX-API-DMAC7.html)
SI (1) SI3864053T1 (cg-RX-API-DMAC7.html)
WO (1) WO2021048280A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4252847A3 (en) 2016-08-15 2023-11-15 Novartis AG Regimens and methods of treating multiple sclerosis using ofatumumab
US20220389109A1 (en) * 2019-09-11 2022-12-08 Novartis Ag Management of conditions other than multiple sclerosis in ofatumumab-treated patients
WO2021204994A1 (en) * 2020-04-09 2021-10-14 Novartis Ag Ofatumumab for treating ms while maintaining serum igg
CA3215371A1 (en) * 2021-04-13 2022-10-20 Shibeshih Mitiku BELACHEW Compositions and methods for treating chronic active white matter lesions / radiologically isolated syndrome
CN117529336A (zh) * 2021-04-14 2024-02-06 诺华股份有限公司 用于治疗亚洲患者的多发性硬化症的奥法木单抗

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100944575B1 (ko) 2002-10-17 2010-02-25 젠맵 에이/에스 Cd20에 대한 인간 모노클로날 항체
UA107557C2 (xx) 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
AR073295A1 (es) * 2008-09-16 2010-10-28 Genentech Inc Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
EP2692343A1 (en) * 2012-08-03 2014-02-05 Forward Pharma A/S Combination therapy for treatment of multiple sclerosis
HK1231413A1 (zh) * 2014-04-29 2017-12-22 Teva Pharmaceutical Industries Ltd. 用於治疗具有高残疾状况的复发-缓解型多发性硬化症(rrms)的患者的拉喹莫德
EP4252847A3 (en) * 2016-08-15 2023-11-15 Novartis AG Regimens and methods of treating multiple sclerosis using ofatumumab

Also Published As

Publication number Publication date
AU2020344154A1 (en) 2022-04-07
EP4230655A2 (en) 2023-08-23
CN114401742A (zh) 2022-04-26
CN118403156A (zh) 2024-07-30
EP3864053B1 (en) 2023-07-05
DK3864053T3 (da) 2023-09-11
JP2026016387A (ja) 2026-02-03
CN114401742B (zh) 2024-05-24
SI3864053T1 (sl) 2023-12-29
CN118436777A (zh) 2024-08-06
MX2022003010A (es) 2022-06-02
US20220298253A1 (en) 2022-09-22
IL290619A (en) 2022-04-01
CA3150947A1 (en) 2021-03-18
KR20220062025A (ko) 2022-05-13
EP4230655A3 (en) 2023-11-01
JP7794735B2 (ja) 2026-01-06
FI3864053T3 (fi) 2023-09-13
EP3864053A1 (en) 2021-08-18
WO2021048280A1 (en) 2021-03-18
JP2022548575A (ja) 2022-11-21
ES2957112T3 (es) 2024-01-11

Similar Documents

Publication Publication Date Title
IL285771A (en) Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator
IL283325A (en) Methods for treatment using adoptive cell therapy
PL4417249T3 (pl) Urządzenia do zabiegów na strukturach biologicznych za pomocą częstotliwości radiowej
SMT202600184T1 (it) Esketamina per il trattamento della depressione
PL3580211T3 (pl) 2-heteroarylo-3-okso-2,3-dihydropirydazyno-4-karboksyamidy do leczenia nowotworu
IL287904A (en) Combination treatment of arthritic disease
LT4034122T (lt) Hiperfenilalaninemijos gydymo būdai
EP4003994A4 (en) TREATMENT OF EVASIVE IMMUNE TUMORS
DK3864053T3 (da) Behandling af rms ved at skifte terapi
IL292502A (en) Therapeutic methods using vadadustat
LT3886799T (lt) Kompozicija, skirta plaukų slinkimo gydymui
PL3697399T3 (pl) Środki terapeutyczne do zastosowania w leczeniu zespołu niespokojnych nóg
PL3952858T3 (pl) Sposób leczenia guzów
EP4355238A4 (en) ELECTROPORATION TREATMENT
EP3999100C0 (en) ENHANCED TREATMENT WITH EYP001
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
EP3991718A4 (en) HAIR TREATMENT METHOD
IL290983A (en) Treatment methods
EA202090266A1 (ru) Ингибиторы mpo для применения в медицине
IL289338A (en) Therapeutic interactions of leucomethylthioninium
IL280968A (en) Combination therapy
EP4073003A4 (en) Plasma water treatment
EP4025203A4 (en) CANCER TREATMENT
EP4069438C0 (en) SKIN TREATMENT SYSTEM
EP3577224A4 (en) NEW TREATMENT FOR NEAT1-ASSOCIATED ILLNESS